Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

S Bringhen; R Mina; AM Cafro; AM Liberati; S Spada; A Belotti; G Gaidano; F Patriarca; R Troia; R Fanin; L De Paoli; G Rossi; A Lombardo; P Bertazzoni; A Palumbo; Pieter Sonneveld; M Boccadoro

doi:10.1038/s41375-018-0024-1

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

S Bringhen, R Mina, AM Cafro, AM Liberati, S Spada, A Belotti, G Gaidano, F Patriarca, R Troia, R Fanin, L De Paoli, G Rossi, A Lombardo, P Bertazzoni, A Palumbo, Pieter Sonneveld, M Boccadoro

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

44 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1803-1807
Number of pages	5
Journal	Leukemia
Volume	32
Issue number	8
DOIs	https://doi.org/10.1038/s41375-018-0024-1
Publication status	Published - 2018

Research programs

EMC OR-01

Access to Document

10.1038/s41375-018-0024-1

http://hdl.handle.net/1765/104934

Cite this

Bringhen, S., Mina, R., Cafro, AM., Liberati, AM., Spada, S., Belotti, A., Gaidano, G., Patriarca, F., Troia, R., Fanin, R., De Paoli, L., Rossi, G., Lombardo, A., Bertazzoni, P., Palumbo, A., Sonneveld, P., & Boccadoro, M. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia, 32(8), 1803-1807. https://doi.org/10.1038/s41375-018-0024-1

@article{c5fa40e6cce44da087a638be78f07f82,

title = "Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study",

author = "S Bringhen and R Mina and AM Cafro and AM Liberati and S Spada and A Belotti and G Gaidano and F Patriarca and R Troia and R Fanin and {De Paoli}, L and G Rossi and A Lombardo and P Bertazzoni and A Palumbo and Pieter Sonneveld and M Boccadoro",

year = "2018",

doi = "10.1038/s41375-018-0024-1",

language = "Undefined/Unknown",

volume = "32",

pages = "1803--1807",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "8",

}

Bringhen, S, Mina, R, Cafro, AM, Liberati, AM, Spada, S, Belotti, A, Gaidano, G, Patriarca, F, Troia, R, Fanin, R, De Paoli, L, Rossi, G, Lombardo, A, Bertazzoni, P, Palumbo, A, Sonneveld, P & Boccadoro, M 2018, 'Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study', Leukemia, vol. 32, no. 8, pp. 1803-1807. https://doi.org/10.1038/s41375-018-0024-1

TY - JOUR

T1 - Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

AU - Bringhen, S

AU - Mina, R

AU - Cafro, AM

AU - Liberati, AM

AU - Spada, S

AU - Belotti, A

AU - Gaidano, G

AU - Patriarca, F

AU - Troia, R

AU - Fanin, R

AU - De Paoli, L

AU - Rossi, G

AU - Lombardo, A

AU - Bertazzoni, P

AU - Palumbo, A

AU - Sonneveld, Pieter

AU - Boccadoro, M

PY - 2018

Y1 - 2018

U2 - 10.1038/s41375-018-0024-1

DO - 10.1038/s41375-018-0024-1

M3 - Article

C2 - 29479061

SN - 0887-6924

VL - 32

SP - 1803

EP - 1807

JO - Leukemia

JF - Leukemia

IS - 8

ER -